Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease

被引:90
作者
Jiménez-Jiménez, FJ
Molina, JA
Aguilar, MV
Meseguer, I
Mateos-Vega, CJ
González-Muñoz, MJ
de Bustos, F
Martínez-Salio, A
Ortí-Pareja, M
Zurdo, M
Martínez-Para, MC
机构
[1] Univ Alcala de Henares, Hosp Principe Asturias, Dept Neurol, Alcala De Henares, Madrid, Spain
[2] Univ Alcala de Henares, Hosp Doce Octubre, Dept Neurol, Alcala De Henares, Madrid, Spain
[3] Univ Alcala de Henares, Hosp Doce Octubre, Dept Biochem, Alcala De Henares, Madrid, Spain
[4] Univ Alcala de Henares, Fac Pharm, Dept Nutr & Bromatol, Alcala De Henares, Madrid, Spain
关键词
Parkinson's disease; transition metals; iron; copper; manganese; zinc; cerebrospinal fluid levels; serum levels;
D O I
10.1007/s007020050073
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We compared CSF and serum levels of iron, copper, manganese, and zinc, measured by atomic absorption spectrophotometry, in 37 patients with Parkinson's disease (PD) and 37 matched controls. The CSF levels of zinc were significantly decreased in PD patients as compared with controls (p < 0.05). The serum levels of zinc, and the CSF and serum levels of iron, copper, and manganese, did not differ significantly between PD-patient and control groups. There was no influence of antiparkinsonian therapy on CSF levels of none of these transition metals. These values were not correlated with age, age at onset, duration of the disease, scores of the Unified Parkinson Disease Rating Scale of the Hoehn and Yahr staging in the PD group, with the exception of CSF copper levels with the duration of the disease (r = 0.38, p < 0.05). These results suggest that low CSF zinc concentrations might be related with the risk for PD, although they could be related with oxidative stress processes.
引用
收藏
页码:497 / 505
页数:9
相关论文
共 40 条
[31]  
MERET S, 1971, CLIN CHEM, V17, P369
[32]  
MOREU E, 1990, R SIGMA BASE DATOS B
[33]  
OLSON AD, 1969, CLIN CHEM, V15, P438
[34]   FERRITIN IN THE CEREBROSPINAL-FLUID OF PATIENTS WITH PARKINSONS-DISEASE [J].
PALL, HS ;
BRAILSFORD, S ;
WILLIAMS, AC ;
LUNEC, J ;
BLAKE, DR .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (09) :803-803
[35]  
PALL HS, 1987, LANCET, V2, P238
[36]  
Pan B. Y., 1997, MOV DISORD S1, V12, P33
[37]   TRANSITION-METALS, FERRITIN, GLUTATHIONE, AND ASCORBIC-ACID IN PARKINSONIAN BRAINS [J].
RIEDERER, P ;
SOFIC, E ;
RAUSCH, WD ;
SCHMIDT, B ;
REYNOLDS, GP ;
JELLINGER, K ;
YOUDIM, MBH .
JOURNAL OF NEUROCHEMISTRY, 1989, 52 (02) :515-520
[38]   A SELECTIVE INCREASE IN PARTICULATE SUPEROXIDE-DISMUTASE ACTIVITY IN PARKINSONIAN SUBSTANTIA NIGRA [J].
SAGGU, H ;
COOKSEY, J ;
DEXTER, D ;
WELLS, FR ;
LEES, A ;
JENNER, P ;
MARSDEN, CD .
JOURNAL OF NEUROCHEMISTRY, 1989, 53 (03) :692-697
[39]  
Takahashi S, 1994, Nihon Ronen Igakkai Zasshi, V31, P865
[40]   REGIONAL METAL CONCENTRATIONS IN PARKINSONS-DISEASE, OTHER CHRONIC NEUROLOGICAL DISEASES, AND CONTROL BRAINS [J].
UITTI, RJ ;
RAJPUT, AH ;
ROZDILSKY, B ;
BICKIS, M ;
WOLLIN, T ;
YUEN, WK .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1989, 16 (03) :310-314